Jun 13,2022

Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems

The study reviews attributes of Dexcom’s fifth-, sixth-, and seventh-generation (G5, G6, and G7) CGM systems.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 13,2022

Explainable Machine Learning for Real-Time Hypoglycemia and Hyperglycemia Prediction and Personalized Control Recommendations

The study assesses the efficiency and effectiveness of machine learning algorithms using CGM data to make ahead-of-time risk predictions and provide insight into an individual’s longer term control, hypoglycemia and hyperglycemia peaks.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 14,2022

Diabetes Devices Market Value to Reach $54.16 Billion by 2030

The global diabetes devices market size is expected to reach USD 54.16 billion by 2030, according to a new report by Grand View Research, Inc., registering a CAGR of 8.2% from 2022 to 2030.

View Analyst & Ambassador Comments
Go to original news
Jun 15,2022

New Animated T1D Explainer

Digibete announces a new animation helping young people and families understand type 1 diabetes.

View Analyst & Ambassador Comments
Go to original news
Jun 15,2022

The Worldwide Self-Monitoring Blood Glucose Devices Industry is Expected to Reach $15 Billion by 2027

The global self-monitoring blood glucose (SMBG) device market is expected to reach a market size worth US$15.013 billion by 2027, growing at a CAGR of 6.39%. This market was valued at US$9.731 billion in 2020.

#bgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Tandem Diabetes Care Welcomes Two New Members to Board of Directors

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today announced the appointments of Myoung Cha and Joao Malagueira as independent members of its board of directors effective June 15, 2022.

View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m. ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Welldoc Granted 31st Patent for First-in-Class Chronic Care Platform

Welldoc®, a digital health leader revolutionizing chronic care, today announced that the company’s 31st patent was granted on June 14, 2022, demonstrating the continued advancement of Welldoc’s first-in-class technology for comprehensive chronic condition management.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems, today announced that it has received CE Mark approval for the next-generation Eversense® E3 CGM System, the longest-lasting system available, with exceptional accuracy.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 16,2022

Brighter's agreement with Erik Lissner as permanent CEO is under negotiation and is expected to be finalized at the end of June

Brighter AB announced on 17 January 2022 that its Board of Directors extended the agreement with Erik Lissner as Acting CEO of Brighter until 15 June 2022 and that an agreement on permanent employment would commence thereafter.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES